69 studies found for:    "Chondrosarcoma"
Show Display Options
Rank Status Study
1 Recruiting Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Conditions: Chondrosarcoma;   Metastatic Chondrosarcoma
Intervention: Drug: pazopanib
2 Active, not recruiting Proton Beam Therapy for Chondrosarcoma
Condition: Chondrosarcoma
Intervention: Procedure: Proton Beam Therapy
3 Recruiting Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base
Condition: Chondrosarcoma
Interventions: Radiation: carbon ion therapy;   Radiation: proton therapy
4 Not yet recruiting Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
Conditions: Solitary Fibrous Tumor;   Extraskeletal Myxoid Chondrosarcoma
Intervention: Drug: Pazopanib
5 Not yet recruiting A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Drug: Everolimus 2.5 mg/day;   Drug: Everolimus 10 mg/day
6 Terminated A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Condition: Chondrosarcoma
Intervention: Drug: PRO95780
7 Recruiting Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
Conditions: Advanced Desmoid Tumor;   Advanced Chondrosarcoma
Intervention: Drug: Imatinib Mesylate
8 Completed A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926;   Drug: Placebo Arm
9 Active, not recruiting Vismodegib in Treating Patients With Advanced Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Drug: vismodegib;   Other: laboratory biomarker analysis
10 Suspended Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Neurofibrosarcoma;   Chondrosarcoma;   Endometrial Stromal Sarcoma;   Mast Cell Sarcoma;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Ovarian Carcinosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib;   Other: laboratory biomarker analysis
11 Recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: vismodegib;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Unknown  Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine
Conditions: Chordoma;   Chondrosarcoma
Intervention: Radiation: Charged Particle Radiation Therapy
13 Recruiting Proton Therapy for Chordomas and/or Chondrosarcomas
Conditions: Chordomas;   Chondrosarcomas
Intervention:
14 Completed A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Conditions: Chondrosarcomas;   Alveolar Soft Part Sarcomas;   Extra Skeletal Myxoid Chondrosarcomas
Intervention: Drug: Perifosine
15 Recruiting High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull
Conditions: Chordoma of Spine;   Chordoma of Sacrum;   Chordoma of Base of Skull;   Chondrosarcoma of the Spine;   Chondrosarcoma of the Sacrum
Intervention: Radiation: High Dose Intensity Modulated Proton Radiation
16 Recruiting Proton Radiation for Chordomas and Chondrosarcomas
Conditions: Chordomas;   Chondrosarcomas
Intervention: Radiation: Proton Therapy
17 Active, not recruiting Trial of Dasatinib in Advanced Sarcomas
Conditions: Rhabdomyosarcoma;   Malignant Peripheral Nerve Sheath Tumors;   Chondrosarcoma;   Sarcoma, Ewing's;   Sarcoma, Alveolar Soft Part;   Chordoma;   Epithelioid Sarcoma;   Giant Cell Tumor of Bone;   Hemangiopericytoma;   Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: Dasatinib
18 Recruiting Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Conditions: Cholangiocarcinoma;   Chondrosarcoma;   Glioma;   Advanced Solid Tumors
Intervention: Drug: AG-120
19 Recruiting Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Conditions: Bone Cancer;   Chondrosarcoma;   Ewing's Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
Interventions: Drug: Feraheme;   Procedure: MR Scan
20 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years